Liver Cancer Causes
Liver Cancer Causes
Liver cancer almost always has a predecessor — which is what makes it one of the most preventable cancers in adults, and why knowing your own risk profile actually changes what happens next.
Chronic hepatitis B: the largest single cause
Worldwide, chronic hepatitis B is the leading cause of liver cancer, and it is the dominant one in China and across much of Asia. The virus does not have to cause cirrhosis first: liver cancer can develop in a liver infected with hepatitis B even when the architecture is still largely preserved, which is why guidelines recommend surveillance for people with chronic infection regardless of how the liver looks on a scan.
The reason hepatitis B is so consequential is that it can persist silently for decades. Many people acquire it at birth or in early childhood, when infection is far more likely to become chronic, and then carry it without symptoms. The virus integrates into liver cells and drives chronic inflammation, and both of those processes increase the chance of a malignant change over time.
The practical message is therefore a test, not a worry: a single blood test establishes whether you carry hepatitis B. If you do, antiviral treatment can suppress the virus and substantially reduce — though not eliminate — the risk of liver cancer, and surveillance every six months finds tumours while they are still treatable. Two things follow from that: treatment and monitoring are complementary, not alternatives, and the monitoring continues even when the virus is well controlled.
Chronic hepatitis C
Hepatitis C causes liver cancer mainly through the cirrhosis it eventually produces, and it is now the one major cause that can be cured: direct-acting antiviral tablets clear the infection in the great majority of people treated, usually over a course of weeks rather than months. That is genuine prevention of liver cancer, because removing the cause stops the ongoing injury.
Two caveats matter. First, if cirrhosis has already developed by the time the virus is cleared, the risk of liver cancer does not disappear — scarred liver tissue remains a place where cancer can start, so surveillance continues after cure. Second, most people with hepatitis C have no symptoms until the liver is significantly damaged, which is why testing rather than symptoms is how it is found. For anyone who might have been exposed, one blood test answers it.
Cirrhosis of any cause
Cirrhosis — scarring that replaces normal liver tissue — is the common ground on which most liver cancers grow, whatever caused it. When hepatocytes are repeatedly damaged and replaced, the liver passes through cycles of inflammation and regeneration, and each cycle increases the chance that a cell acquires the changes that make it malignant.
That is why the cause matters less than the presence of scarring: cirrhosis from hepatitis B, hepatitis C, alcohol, metabolic liver disease or a rarer condition such as haemochromatosis or primary biliary cholangitis all carry a risk of liver cancer that is high enough to justify surveillance every six months. It is also why a person with cirrhosis needs that surveillance even if the underlying condition is being treated successfully — the scar is the risk factor, and it does not go away.
Alcohol
The relationship between alcohol and liver cancer is dose-dependent and cumulative. Heavy drinking over years produces fatty change, then inflammation, then cirrhosis, and each of those stages raises risk. Alcohol also acts alongside other causes rather than instead of them: in someone with hepatitis B or C, the combination is significantly worse than either alone, which matters because both exposures are common in the same populations.
For practical purposes, the important questions are how much and for how long, and whether the liver is already scarred. Reducing or stopping alcohol lowers further risk of progression, and in a damaged liver it is one of the few things entirely within a patient's control. Anyone with cirrhosis should be advised to stop altogether rather than to moderate.
Fatty liver disease, obesity and diabetes
The fastest-growing group of liver cancer patients in many countries no longer has a viral cause. Metabolic dysfunction-associated fatty liver disease covers a spectrum from simple fat accumulation to steatohepatitis with inflammation and fibrosis, and when fibrosis advances to cirrhosis the cancer risk follows the same path as any other cause.
Two characteristics make this group easy to miss. First, the disease is usually asymptomatic and is often discovered incidentally on an ultrasound done for something else. Second, because the population is large, even a modestly increased risk translates into a substantial number of cancers — which is why liver cancer is now seen in people who have never drunk heavily and who have never carried a hepatitis virus. Type 2 diabetes and central obesity each add to the risk, and both are modifiable: weight reduction, physical activity and control of blood sugar and lipids all reduce progression of the underlying liver disease.
Aflatoxin and other exposures
Aflatoxin B1 is a toxin produced by moulds that grow on poorly stored maize, groundnuts, rice and other staples. It is classified as a Group 1 human carcinogen and is a well-established cause of liver cancer, with a striking interaction: in populations where hepatitis B is also common, the two together increase risk far more than either does alone. This is a food-storage problem as much as a medical one, and it is largely preventable by drying and storing grain properly and discarding anything mouldy or discoloured.
Several other exposures are less common but worth knowing. Long-standing smoking contributes to liver cancer risk, particularly in combination with alcohol or viral hepatitis. Rare inherited conditions — haemochromatosis, where the body absorbs too much iron, and alpha-1 antitrypsin deficiency — increase risk through the liver damage they cause. Prolonged use of some anabolic steroids and certain herbal preparations has been associated with liver tumours. If any of these apply to you, they are worth mentioning at a consultation.
Family history
A family history of liver cancer raises risk, and the reason is partly shared environment and partly shared biology. Household clustering of hepatitis B is common because of transmission in early childhood, so several relatives with the same infection is expected rather than evidence of an inherited defect. Alongside that, there are genetic variants — for example in metabolic liver disease — that influence how quickly fibrosis progresses in response to the same exposure.
Two practical consequences follow. Tell your doctor if a parent or sibling has had liver cancer, including at what age and whether they carried hepatitis B: it may affect when surveillance starts and how closely you are monitored. And if several close relatives are affected, particularly at young ages and without a viral cause, ask whether a specialist hepatology assessment is appropriate for the family as a whole.
Four beliefs that cost time
"No hepatitis, no risk"
Metabolic liver disease, alcohol and, less commonly, inherited conditions all cause liver cancer without any viral infection. The fastest-growing group of patients in many countries has none of the classic viral risk factors.
"My liver blood tests are normal"
Routine liver enzymes can be unremarkable in someone with cirrhosis or with a small tumour, and people with chronic hepatitis B often have normal results for years. Normal blood tests do not replace surveillance imaging.
"Herbal products protect the liver"
Some do have a role in specific conditions under supervision, but herbal and dietary supplements are also a recognised cause of drug-induced liver injury. In a damaged liver, an unregulated product is a risk, not a safeguard.
"Only heavy drinkers get alcohol-related liver cancer"
Risk rises with cumulative intake rather than appearing at a threshold, and alcohol multiplies the risk carried by viral hepatitis. Moderate amounts over many years are not neutral, particularly in a liver that is already scarred.
If any of this applies to you
Establish your status
One blood test covers hepatitis B and hepatitis C. If either is present, treatment may be available and surveillance certainly is.
Check whether you need surveillance
See prevention and surveillance for who should have an ultrasound and AFP test every six months, and what the evidence supports.
Do not wait for a symptom
If something has already changed — swelling, jaundice, weight loss — move to symptoms and early warning signs and arrange assessment.